144 related articles for article (PubMed ID: 34009323)
21. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
Kam N; Perera K; Zomer E; Liew D; Ademi Z
Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels.
Pandya A; Asch DA; Volpp KG; Sy S; Troxel AB; Zhu J; Weinstein MC; Rosenthal MB; Gaziano TA
JAMA Netw Open; 2018 Sep; 1(5):e182008. PubMed ID: 30646152
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
25. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
[TBL] [Abstract][Full Text] [Related]
26. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Burger PM; Dorresteijn JAN; Fiolet ATL; Koudstaal S; Eikelboom JW; Nidorf SM; Thompson PL; Cornel JH; Budgeon CA; Westendorp ICD; Beelen DPW; Martens FMAC; Steg PG; Asselbergs FW; Cramer MJ; Teraa M; Bhatt DL; Visseren FLJ; Mosterd A; ; ;
Eur J Prev Cardiol; 2023 Dec; 30(18):1950-1962. PubMed ID: 37409348
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
28. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
29. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.
Jaspers NEM; Blaha MJ; Matsushita K; van der Schouw YT; Wareham NJ; Khaw KT; Geisel MH; Lehmann N; Erbel R; Jöckel KH; van der Graaf Y; Verschuren WMM; Boer JMA; Nambi V; Visseren FLJ; Dorresteijn JAN
Eur Heart J; 2020 Mar; 41(11):1190-1199. PubMed ID: 31102402
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
31. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
33. Optimizing cardiovascular disease risk screening in a low-resource setting: cost-effectiveness of program modifications in Sri Lanka modelled with nationally representative survey data.
Wijemunige N; Rannan-Eliya RP; van Baal P; O'Donnell O
BMC Public Health; 2023 Sep; 23(1):1792. PubMed ID: 37715157
[TBL] [Abstract][Full Text] [Related]
34. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
[TBL] [Abstract][Full Text] [Related]
35. Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I.
Jülicher P; Varounis C
Eur Heart J Qual Care Clin Outcomes; 2022 May; 8(3):342-351. PubMed ID: 33502472
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
39. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease.
van Trier TJ; Snaterse M; Hageman SHJ; Ter Hoeve N; Sunamura M; Moll van Charante EP; Galenkamp H; Deckers JW; Martens FMAC; Visseren FLJ; Scholte Op Reimer WJM; Peters RJG; Jørstad HT
Eur J Prev Cardiol; 2023 May; 30(7):601-610. PubMed ID: 36757680
[TBL] [Abstract][Full Text] [Related]
40. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
